Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 11/20 | 0.58 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.52 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 8/20 | 0.51 |
| ▸ | RARB | P10826 | 10/20 | 0.49 |
| ▸ | RARG | P13631 | 9/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6871146 | 1.00 | RARA (0.58) | RARACYP26A1CYP26B1RXRARARB | |
| SCHEMBL6870556 | 0.83 | RARA (0.45) | RARARXRARARBRARG | |
| SCHEMBL6870553 | 0.83 | RARA (0.45) | RARARXRARARBRARG | |
| SCHEMBL14003301 | 0.81 | CYP26A1 (0.71) | RARACYP26A1CYP26B1RXRARARB | |
| SCHEMBL6876892 | 0.81 | RXRA (0.56) | RARACYP26A1CYP26B1RXRARARB | |
| SCHEMBL6876888 | 0.81 | RXRA (0.56) | RARACYP26A1CYP26B1RXRARARB | |
| SCHEMBL6928269 | 0.81 | PGR (0.47) | RARARXRARARBRARGABCB1 | |
| SCHEMBL5360894 | 0.81 | RXRA (0.62) | RARACYP26A1CYP26B1RXRARARB | |
| SCHEMBL5360900 | 0.81 | RXRA (0.62) | RARACYP26A1CYP26B1RXRARARB | |
| SCHEMBL6821889 | 0.78 | RARA (0.60) | RARACYP26A1CYP26B1RXRARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030135053-A1 | For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics | BERNARDON JEAN-MICHEL | 2003-07-17 | — | — | US | claimed |
| US-20030060491-A1 | Bicyclic aromatic compounds | BERNARDON JEAN-MICHEL (FR) | 2003-03-27 | — | — | US | claimed |
| EP-0832081-B1 | BICYCLIC-AROMATIC COMPOUNDS | GALDERMA RECH DERMATOLOGIQUE (FR) | 2003-01-29 | — | — | EP | claimed |
| US-6825360-B1 | Bicyclic aromatic compounds | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-11-30 | — | — | US | disclosed |
| US-20030135053-A1 | For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics | BERNARDON JEAN-MICHEL | 2003-07-17 | — | — | US | disclosed |
| US-20030060491-A1 | Bicyclic aromatic compounds | BERNARDON JEAN-MICHEL (FR) | 2003-03-27 | — | — | US | disclosed |
| US-6515021-B1 | Bicyclic aromatic compounds | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2003-02-04 | — | — | US | disclosed |
| EP-0832081-B1 | BICYCLIC-AROMATIC COMPOUNDS | GALDERMA RECH DERMATOLOGIQUE (FR) | 2003-01-29 | — | — | EP | disclosed |
| US-6147255-A | TOPICAL AND SYSTEMIC TREATMENT OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH KERATINIZATION DISORDER WHICH HAS EFFECT ON DIFFERENTIATION AND ON PROLIFERATION | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-11-14 | — | — | US | disclosed |
| EP-0832081-A1 | BICYCLIC-AROMATIC COMPOUNDS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997033881-A1 | BICYCLIC-AROMATIC COMPOUNDS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1997-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060491-A1 | Bicyclic aromatic compounds | MITF, TYR, PAH | RARA 451/4885CYP26A1 137/4885CYP26B1 220/4885 |
| US-20030135053-A1 | For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics | MITF, TYR, PAH | RARA 52/4885CYP26A1 119/4885CYP26B1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.